Tripos Releases Newest SYBYL-X Discovery Software for Computational Chemistry and Molecular Modeling
ST. LOUIS–(BUSINESS WIRE)–Tripos™, a leading provider of drug discovery informatics products and services, today announced the release and general availability of the latest version of its flagship product line, SYBYL®-X. The new release contains an array of tools and solutions for discovery scientists and computational chemists, packaged under one convenient licensing program or available as individually selected packages.
“SYBYL-X is accessible, discovery-relevant science at its best. Our core SYBYL technology has always been known and respected for its solid scientific superiority, and that’s why SYBYL is one of the most widely installed scientific software solutions globally,” says Richard D. Cramer, Ph.D, Tripos’ Chief Scientific Officer. “This latest offering provides unprecedented ability to find novel R-groups predicted to have high potency and optimize multiple design parameters, providing discovery scientists with powerful lead optimization capabilities.”
SYBYL-X is available for Windows® and Linux® and includes a new R-group virtual screening capability, which quickly and easily provides users with superior pIC50 forecasts for maximizing lead optimization. Additionally, the new Surflex v2.415 receptor-specific optimizations, of receptor geometry and energy function, are also especially well suited for data-rich lead optimization.
Tripos’ Chief Operating Officer, Patrick Flanagan, added, “From a business perspective, SYBYL-X licensing has been simplified, and the availability of SYBYL-X on the popular Windows platforms makes it easier than ever for discovery scientists to access the scientific capabilities inherent in SYBYL, without investing in specialized hardware. In a tight economy, researchers need to make smart investments, and Tripos offers programs that lower the total cost of ownership, without compromising access to the best software.”
About Tripos
Tripos, a Certara™ Company, is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become marketed drugs, foods, flavorings and fragrances. Headquartered in St. Louis, Missouri, Tripos serves more than 1,000 customers spanning over 46 countries.
About Certara
Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Tripos provides innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and scientific services to improve productivity and decision-making in clinical drug development. Certara focuses on reducing the barriers between the phases of research to speed discoveries in chemistry, and enabling pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
